scispace - formally typeset
R

Richard Heller

Researcher at University of South Florida

Publications -  220
Citations -  13730

Richard Heller is an academic researcher from University of South Florida. The author has contributed to research in topics: Electroporation & Electrochemotherapy. The author has an hindex of 51, co-authored 215 publications receiving 12950 citations. Previous affiliations of Richard Heller include Florida College & College of Health Sciences, Bahrain.

Papers
More filters
Journal ArticleDOI

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

TL;DR: It is shown that VEGF expression correlates with Stat3 activity in diverse human cancer cell lines and indicates that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers.
Journal ArticleDOI

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.

TL;DR: It is proposed that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.
Journal ArticleDOI

The orderly progression of melanoma nodal metastases.

TL;DR: The null hypothesis tested was whether nodal metastases from malignant melanoma occurred in equal proportions among sentinel and nonsentinel nodes, and the probability that all seven unpaired observations would demonstrate that involvement of the sentinel node is 0.008.
Journal ArticleDOI

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

TL;DR: This report describes the first human trial, to the authors' knowledge, of gene transfer utilizing in vivo DNA electroporation and indicated this modality to be safe, effective, reproducible, and titratable.
Journal ArticleDOI

Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy.

TL;DR: ECT was shown to be an effective local treatment and was effective regardless of the histological type of the tumour, and offers an approach to the treatment of cutaneous and subcutaneous tumours in patients with minimal adverse side-effects and with a high response rate.